蛋白转化酶 (Subtilisin/Kexin) 9型抑制:脂质控制中的重大进步
Rishi Rikhi1, Michael D Shapiro1
1Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine Winston-Salem, NC, US.
European cardiology
|July 17, 2023
概括
抑制蛋白转化酶亚提利辛/凯9型 (PCSK9) 显著降低了LDL胆固醇. 本综述涵盖了目前和新兴的PCSK9疗法,用于降低心血管疾病风险.
科学领域:
- 生物化学 生物化学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 的发现彻底改变了对胆固醇平衡的理解.
- PCSK9突变会影响LDL胆固醇水平和心血管疾病风险.
- 抑制PCSK9增强了肝细胞上的LDL受体密度,增加了LDL清除.
研究的目的:
- 审查各种PCSK9抑制策略的疗效,安全性和临床使用情况.
- 突出目前针对PCSK9的治疗方法和正在开发的新方法.
主要方法:
- 对PCSK9抑制剂的随机对照试验的综述.
- 对PCSK9功能和功能障碍的遗传研究的分析.
- 评估新兴的PCSK9向策略,包括基因沉默,基因编辑和疫苗.
主要成果:
- 皮下单克隆抗体 (evolocumab,alirocumab) 和inclisiran显示显著降低了LDL胆固醇.
- 遗传研究证实了PCSK9功能与心血管风险之间的联系.
- 新型PCSK9疗法对未来的心血管疾病管理有希望.
结论:
- 抑制PCSK9是一种有效的策略,可以降低LDL胆固醇,减少动脉样硬化心血管疾病的风险.
- 目前已有多种针对PCSK9的治疗方法,并且正在开发中,可用于各种临床应用.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
702
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
702
Lipid Digestion
92.3K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
92.3K
Glucagon-like Receptor Agonists
364
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
364
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Lipid Absorption
536
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
536
Lipid Catabolism
80
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
80


